Skip to main content
Premium Trial:

Request an Annual Quote

FDA Clears Idaho Technology's Biothreat Tests

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared two pathogen-detection kits, including one for tularemia and one for a plague, made by Idaho Technology, the company said today.
 
The tests will run on the company’s Joint Biological Agent Identification and Diagnostic System, which was selected by the US Department of Defense in 2003 for biothreat detection, ITI said. These tests can use blood, sputum, positive blood cultures, and colonies and can generate results in under four hours.
 
The cleared kits identify Yersinia pestis and Francisella tularensis, both of which are classified as Category A Select Agents by the Centers for Disease Control and Prevention, which means they are considered high-priority biothreats to national security.
 
The clinical trials for the JBAIDS Plague and the JBAIDS Tularemia detection kits were conducted by the Army, Navy, and Air Force, the company said.
 
The company also plans to seek FDA clearance for its JBAIDS Brucellosis Detection Kit, ITI added.

The Scan

Tennessee's COVID-19 Sequencing

The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples.

Sanction Violation Charges

A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports.

Prenetics to Go Public Through SPAC

Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx.

Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair

In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.